Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Consider This Conditioning Regimen for Allogeneic HSCT
Biol Blood Marrow Transplant; ePub 2016 Nov 2; Kebriaei, et al
Intravenous busulfan (Bu) combined with clofarabine (Clo) controlled disease and was safe in a study involving 107 individuals with acute lymphoblastic leukemia (ALL).
Participants had ALL and were undergoing allogeneic hematopoietic stem cell transplantation via matched sibling (n=52) or matched unrelated donor (n=55) transplant. Clo 40 mg/m2 was given once daily, followed by Bu infused over 4 hours daily for 4 days. Hematopoietic cell infusion was then given after 2 days of rest. Among the results:
- 2-year progression-free survival in patients with CR1 disease was 62%; in those with CR2 and more advanced disease it was 34% and 35%, respectively.
- Non-relapse mortality rate was 10% at 100 days and 31% at 2 years.
- 18% of patients developed extensive chronic GVHD.
- 2-year overall survival in patients with CR1 disease was 70%; in those with CR2 and more advanced disease it was 57% and 35%, respectively.
Kebriaei P, Bassett R, Lyons G, et al. Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: Long-term study results. [Published online ahead of print November 2, 2016]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2016.11.001.